Therapeutic outcomes of CAL/BDP PAD-based cream in patients with mild-to-moderate psoriasis: insights from four case reports.

Topical medications are commonly used to manage mild-to-moderate psoriasis as adjunctive treatments in patients receiving phototherapy, systemic agents or biologic therapies. Amongst available topical options, the fixed-dose combination of calcipotriol (CAL) and betamethasone dipropionate (BDP) has demonstrated efficacy and tolerability in clinical trials, with most adverse events being mild and transient local reactions. CAL/BDP has recently been formulated as a cream using polyaphron dispersion (PAD) technology to improve its rheological behaviour and sensory characteristics. We describe the use of CAL/BDP PAD-based cream specifically in patients with mild-to-moderate psoriasis across four Italian centres. The first case involves a man with mild-to-moderate scalp psoriasis, in whom CAL/BDP PAD-based cream was effective in this high-impact disease location. The second case focuses on a patient with pretibial psoriasis, a difficult-to-treat site. The third case is of a woman with palmoplantar psoriasis who reported clinical improvement in the lesions and increased treatment compliance compared with her previous therapies. The last case describes the concomitant use of CAL/BDP PAD-based cream with a biologic drug, resulting in optimized lesion clearance. CAL/BDP PAD-based cream appears promising for managing psoriasis in specific contexts such as lesions in difficult-to-treat areas or residual disease during biologic therapy. Further real-world data and clinical observations will be important to clarify how this formulation can be integrated into individualized management strategies for mild-to-moderate psoriasis.